Pereira Chirag, Martis Manohar, D'Souza Rohan, Tauro Leo Francis
Department of General Surgery, Father Muller Medical College and Hospital Mangalore, India.
Curr Health Sci J. 2021 Jul-Sep;47(3):348-352. doi: 10.12865/CHSJ.47.03.03. Epub 2021 Sep 30.
Molecular classification of breast cancer is commonly done to determine response to therapy and cancer prognosis. Aim of the study was to compare prevalence of molecular subtypes of breast cancer in our institute using immunohistochemistry, including Ki-67, and correlate it with clinical and pathological prognostic factors.
300 cases of invasive breast cancer were included in the study. Average age at time of diagnosis was 44 years and average size of tumor was 3.4cms. Invasive ductal carcinoma was the most common histological type (75.3%). The most common molecular subtype was triple negative (34.3%) followed by Luminal B (33.4%), luminal A (17%) and Her-2 positive (15.3%). Large size and poorly differentiated tumors were predominantly triple negative tumors while lymph node metastasis was most commonly seen in Her-2 positive tumors.
Molecular subtype of breast carcinoma should routinely be done for all cases of carcinoma breast as it allows to identify aggressive tumors and target therapy accordingly.
乳腺癌的分子分类通常用于确定治疗反应和癌症预后。本研究的目的是使用免疫组织化学方法（包括Ki-67）比较我院乳腺癌分子亚型的患病率，并将其与临床和病理预后因素相关联。
本研究纳入300例浸润性乳腺癌病例。诊断时的平均年龄为44岁，肿瘤平均大小为3.4厘米。浸润性导管癌是最常见的组织学类型（75.3%）。最常见的分子亚型是三阴性（34.3%），其次是Luminal B（33.4%）、Luminal A（17%）和Her-2阳性（15.3%）。肿瘤体积大且分化差的主要是三阴性肿瘤，而淋巴结转移最常见于Her-2阳性肿瘤。
对于所有乳腺癌病例，应常规进行乳腺癌分子亚型检测，因为这有助于识别侵袭性肿瘤并据此进行靶向治疗。
